Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind, crossover,
C Di Lorenzo1, S N Reddy, J Villanueva-Meyer
1Department of Pediatrics, Harbor-UCLA Medical Center, Torrance.
Insights
Cisapride improved duodenal motility in children with chronic intestinal pseudoobstruction but did not enhance gastric emptying. This study assessed cisapride
Area of Science:
- Pediatric Gastroenterology
- Gastrointestinal Motility Disorders
Background:
- Chronic intestinal pseudoobstruction (CIPO) significantly impacts children's quality of life, often necessitating specialized feeding.
- Understanding the effects of prokinetic agents like cisapride is crucial for managing CIPO symptoms.
Purpose of the Study:
- To evaluate the efficacy of cisapride in improving gastrointestinal motility and gastric emptying in pediatric patients with CIPO.
- To determine if cisapride can positively influence the severe motility abnormalities characteristic of CIPO.
Main Methods:
- A double-blind, randomized crossover study involving 20 children with CIPO.
- Utilized antroduodenal manometry to record motility and 99mTc-labeled meals to assess gastric emptying over 5 days.
- Administered cisapride (0.3 mg/kg t.i.d.) or placebo with a 2-day washout period.
Main Results:
- Cisapride significantly increased the postprandial duodenal motility index (P < 0.05).
- No significant effect of cisapride was observed on antral motility.
- Cisapride did not alter the delayed gastric emptying, with no significant changes in T1/2 or R60.
Conclusions:
- Cisapride enhances postprandial duodenal motility in children with CIPO.
- Cisapride does not improve the significant delay in gastric emptying observed in these patients.
- Further research may be needed to explore alternative treatments for gastric emptying issues in pediatric CIPO.
Abstract:
To assess the effect of cisapride on gastrointestinal motility and gastric emptying in children with chronic intestinal pseudoobstruction, 20 children (mean age, 4.9 years; 14 female and 6 male) who required special means of alimentation or who had severe symptoms confirmed by diary during 2 weeks before the study were studied. A motility catheter with recording sites in the antrum and duodenum was placed on the first day of the study and remained in place until the end of the 5-day study. Cisapride (0.3 mg/kg PO t.i.d.) or placebo was given in double-blind randomized crossover fashion, with a 2-day "washout" interval. Antroduodenal motility was recorded on days 2 and 5. Recording consisted of 4 hours of fasting and 2 hours after a complex liquid meal labeled with 99mTc. Gastric emptying was assessed for 1 hour after the meal. Based on manometry, 16 patients had neuropathic and 4 patients had myopathic disorders. Cisapride had no effect on the discrete, qualitative abnormalities found in individual records. Cisapride increased the postprandial duodenal motility index from 1180 +/- 256 mm Hg/30 min after placebo to 2385 +/- 430 mm Hg/30 min (P less than 0.05) but had no significant effect on the antral motility index. Cisapride did not alter the profound delay in gastric emptying; time to reach 50% of initial activity (T1/2) was 105 +/- 20 vs. 93 +/- 19 minutes and percentage of retention after 60 minutes (R60) 56% +/- 4% vs. 58% +/- 4% in control vs. cisapride, respectively. In summary, in children with chronic intestinal pseudoobstruction, cisapride increased postprandial duodenal motility but did not improve gastric emptying.
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...


